U.S. Government Was Informed of EpiPen Overcharging in 2009
Mylan NV's EpiPen allergy shots sit on display for a photograph in Princeton, Illinois, U.S., on Friday, Aug. 26, 2016.
Photographer: Daniel Acker/BloombergThis article is for subscribers only.
The U.S. government was informed in 2009 that Mylan NV’s EpiPen allergy shots were misclassified under Medicaid pricing rules, resulting in “significant” overcharging of taxpayers, Senator Charles Grassley said.
Grassley, an Iowa Republican, asked the Department of Health and Human Services inspector general to hand over records related to its notification seven years ago that the Center for Medicare and Medicaid Services was overpaying for the allergy shot.